Search

Efinaconazole

It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia. … Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis.

Crotalus scutulatus antivenin

Since it was approved by the Food and Drug Administration in October 2000, crotalidae poyvalent immune Fab (CroFab) has largely replaced previously used crotaline antivenom. … Specimens with type A venom, which cause a different pattern of injury than other rattlesnakes, have been reported in southern California, Nevada, Utah, Arizona, Texas, and New Mexico [L2856].

Zinc phenolsulfonate

BBIBP-CorV

As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials. … Investigation shows this vaccine induces neutralizing antibodies in several mammalian species while also showing protective efficacy with SARS-CoV-2 challenge in rhesus macaques[A219763].

Indium In-111 pentetate

Indium In-111 pentetate disodium is a radioactive diagnostic indicated for use in radionuclide cisternography. … Decay of In-111 by electron capture allows for detection with a gamma camera for visualization of the brain and spinal column.

Cocarboxylase

The coenzyme form of Vitamin B1 present in many animal tissues. It is a required intermediate in the pyruvate dehydrogenase complex and the ketoglutarate dehydrogenase complex.

Toripalimab

It was first approved in China in December 2018 for the treatment of unresectable or metastatic melanoma in previously treated patients. … The proliferation of some cancers can be attributed, at least in part, to the suppression of host tumor surveillance.

Eplontersen

This approval was based on positive results demonstrated in the 35-week interim analysis from the Phase 3 NEURO-TTRansform study, where a consistent improvement in the Neuropathy Impairment Score +7 (mNIS … [A262975] Hereditary transthyretin-mediated amyloidosis is caused primarily by pathogenic variants of the TTR gene, leading to the formation and thus accumulation of insoluble and misfolded amyloid in

Bendazac

Bendazac, however, has since been withdrawn or discontinued in various international regions due to its capability or risk for eliciting hepatotoxicity [A39891, A39892, A39893, L4778] in patients although … the denaturation of proteins - an effect that has primarily proven useful in managing and delaying the progression of ocular cataracts [A39863.

Plozasiran

[L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603] … Plozasiran contains a covalently linked ligand containing three N-acetylgalactosamine (GalNAc) residues to facilitate delivery to hepatocytes where it works to reduce triglyceride levels.